Cargando…

Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System

BACKGROUND: Evidence on mortality risks associated with MS-immunotherapies during the SARS-CoV2 pandemic derived thus far mainly from single country experiences. OBJECTIVE: In this analysis, we aim to determine the frequency of COVID-19 associated fatality reports of patients receiving an MS-immunot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pistor, Maximilian, Hoepner, Robert, Hoepner, Andreas G.F., Lin, Yanan, Jung, Simon, Bassetti, Claudio L., Chan, Andrew, Salmen, Anke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551667/ https://www.ncbi.nlm.nih.gov/pubmed/36237201 http://dx.doi.org/10.1177/17562864221129383

Ejemplares similares

Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA’s Adverse Event Reporting System
por: Pistor, Maximilian, et al.
Publicado: (2021)

The impact of immunotherapies on COVID-19 case fatality rates during the US vaccination campaign: a multidisciplinary open data analysis using FDA Adverse Event Reporting System and Our World in Data
por: Salmen, Anke, et al.
Publicado: (2023)

Application of the “risk of ambulatory disability” (RoAD) score in a “real‐world” single‐center multiple sclerosis cohort
por: Pistor, Maximilian, et al.
Publicado: (2022)

Vitamin D supplementation differentially affects seasonal multiple sclerosis disease activity
por: Miclea, Andrei, et al.
Publicado: (2017)

Socioeconomic and Regional Disparities in Industry-Sponsored Clinical Trials in Multiple Sclerosis
por: Marti, Stefanie, et al.
Publicado: (2023)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
por: Hoepner, Robert, et al.
Publicado: (2014)

Reliable brain morphometry from contrast‐enhanced T1w‐MRI in patients with multiple sclerosis
por: Rebsamen, Michael, et al.
Publicado: (2022)

Vaccine Hesitancy in Patients With Multiple Sclerosis: Preparing for the SARS-CoV-2 Vaccination Challenge
por: Diem, Lara, et al.
Publicado: (2021)

c-Jun N-Terminal Kinase as a Therapeutic Target in Experimental Autoimmune Encephalomyelitis
por: Bagnoud, Maud, et al.
Publicado: (2020)

Is COVID‐19 severity associated with reduction in T lymphocytes in anti‐CD20‐treated people with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?
por: Hoepner, Robert, et al.
Publicado: (2022)

Prediction of conversion to multiple sclerosis using the 2017 McDonald and 2016 MAGNIMS criteria in patients with clinically isolated syndrome: a retrospective single-centre study
por: Miclea, Andrei, et al.
Publicado: (2019)

An algorithm using clinical data to predict the optimal individual glucocorticoid dosage to treat multiple sclerosis relapses
por: Gili-Kovács, Judit, et al.
Publicado: (2021)

Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis
por: Thiele née Schrewe, Lisa, et al.
Publicado: (2020)

Predicting conversion to multiple sclerosis in patients with radiologically isolated syndrome: a retrospective study
por: Chaloulos-Iakovidis, Panagiotis, et al.
Publicado: (2021)

Multiple sclerosis as a model to investigate SARS‐CoV‐2 effect on brain atrophy
por: Rebsamen, Michael, et al.
Publicado: (2022)

1,25-OH(2) vitamin D(3) and AKT-inhibition increase glucocorticoid induced apoptosis in a model of T-cell acute lymphoblastic leukemia (ALL)
por: Pistor, Maximilian, et al.
Publicado: (2018)

Pathological cerebrospinal fluid protein concentration and albumin quotient at relapse predicts short-term disability progression in multiple sclerosis: a retrospective single center observational study
por: Diem, Lara, et al.
Publicado: (2020)

Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis
por: Hoepner, Robert, et al.
Publicado: (2019)

A Brief Review of the Effects of Vitamin D on Multiple Sclerosis
por: Miclea, Andrei, et al.
Publicado: (2020)

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients
por: Hammer, Helly, et al.
Publicado: (2022)

Multidimensional phenotyping of the post‐COVID‐19 syndrome: A Swiss survey study
por: Diem, Lara, et al.
Publicado: (2022)

Fatigue in Post-COVID-19 Syndrome: Clinical Phenomenology, Comorbidities and Association With Initial Course of COVID-19
por: Diem, Lara, et al.
Publicado: (2022)

Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations
por: Ayzenberg, Ilya, et al.
Publicado: (2016)

Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age
por: Briner, Myriam, et al.
Publicado: (2019)

In Vivo and In Vitro Evidence for an Interplay between the Glucocorticoid Receptor and the Vitamin D Receptor Signaling
por: Bagnoud, Maud, et al.
Publicado: (2023)

Age‐dependent variation of female preponderance across different phenotypes of multiple sclerosis: A retrospective cross‐sectional study
por: Miclea, Andrei, et al.
Publicado: (2018)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course
por: Zoehner, Greta, et al.
Publicado: (2019)

Feelings of loneliness, COVID-19-specific-health anxiety and depressive symptoms during the first COVID-19 wave in Swiss persons with multiple sclerosis
por: Hoepner, Robert, et al.
Publicado: (2022)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients
por: Özdemir, Berna C., et al.
Publicado: (2023)

Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis
por: Wang, QuanQiu, et al.
Publicado: (2018)

No optical coherence tomography changes in premanifest Huntington's disease mutation carriers far from disease onset
por: Schmid, Rahel Dominique, et al.
Publicado: (2022)

Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune‑related adverse events among cancer patients
por: Özdemir, Berna C., et al.
Publicado: (2023)

The Real-World Experiences of Persons With Multiple Sclerosis During the First COVID-19 Lockdown: Application of Natural Language Processing
por: Chiavi, Deborah, et al.
Publicado: (2022)

Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies
por: Friedli, Christoph, et al.
Publicado: (2021)

Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations
por: Remlinger, Jana, et al.
Publicado: (2023)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Different Fumaric Acid Esters Elicit Distinct Pharmacologic Responses
por: Wipke, Brian T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pk9097cv7c84mnfdhue38seo0p